AR045791A1 - Derivados de triazol sustituidos como antagonistas de oxitocina - Google Patents

Derivados de triazol sustituidos como antagonistas de oxitocina

Info

Publication number
AR045791A1
AR045791A1 ARP040103392A ARP040103392A AR045791A1 AR 045791 A1 AR045791 A1 AR 045791A1 AR P040103392 A ARP040103392 A AR P040103392A AR P040103392 A ARP040103392 A AR P040103392A AR 045791 A1 AR045791 A1 AR 045791A1
Authority
AR
Argentina
Prior art keywords
alkyl
nr7r8
alkoxy
nr7c
triazole
Prior art date
Application number
ARP040103392A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR045791A1 publication Critical patent/AR045791A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (1) en la que V, W, X e Y, que pueden ser iguales o diferentes, representan C-R6 o N; Z es C-H o N; R1 se selecciona entre: (i) un anillo fenilo sustituido con 2 o más sustituyentes, que pueden ser iguales o diferentes, cada uno seleccionado independientemente entre halo, alquilo C1-6, alcoxi C1-6, ciano, C(O)NR7R8, NR7R8, NR7C(O)R10 y N[C(O)R10]2; y (ii) un anillo heterocíclico aromático de 5 a 7 miembros que contiene 1-3 heteroátomos seleccionados entre N, O y S y los N-óxidos del mismo; estando dicho anillo opcionalmente sustituido con 2 o más sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halo, alquilo C1-6. alcoxi C1-6, ciano, C(O)NR7R8, NR7R8, NR7C(O)R10 y N[C(O)R10]2; R2 se selecciona entre: (i) H, OH, OR9, NR7R8, NR7C(O)R10 y N[C(O)R10]2; (ii) un heterociclo de 5-7 miembros unido a N, que contiene 1-3 heteroátomos seleccionados entre N, O y S; estando dicho anillo opcionalmente sustituido con 1 o más grupos seleccionados entre alquilo C1-6, alcoxi C1-6 y C(O)NR7R8; y (iii) alquilo C1-6 opcionalmente sustituido con un heterociclo de 5-7 miembros unido a N, que contiene 1-3 heteroátomos seleccionados entre N, O y S; R3 se selecciona entre H y alquilo c1- 6; R4 se selecciona entre H, alquilo C1-6 y OR9; R5 se selecciona entre halo, alquilo C1-6, alcoxi C1-6, NR7R8, NR7C(O)R10 y N[C(O)R10]2; R6 se selecciona entre H, halo, alquilo C1-6, alcoxi C1-6, ciano, NR7R8, NR7C(O)R10, N[C(O)R10]2 y C(O)NR7R8; R7 y R8, que pueden ser iguales o diferentes, se seleccionan entre H y alquilo C1-6; R9 es alquilo C1-6, que está opcionalmente sustituido con 1 o más grupos, cada uno seleccionado independientemente entre alcoxi C1-6 y un heterociclo de 5-7 miembros unido a N, que contiene 1-3 heteroátomos seleccionados entre N, O y S; y R10 se selecciona entre alquilo C1-6 y alcoxi C1-6; un tautómero de los mismos o una sal farmacéuticamente aceptable, solvato o polimorfo de dicho compuesto o tautómero; con la condición de que el compuesto de fórmula (1)no sea: 3-etil-5-(4-imidazol-1-ilfenil)-4-(4-metoxifenil)-4H-[1,2,4]triazol, 3-(3´,5´-diclorobifenil-4-il)-4-(2-metoxifenil)-5-metil-4H-[1,2,4]triazol, 3-(3´,5´-bis-trifluorometilbifenil- 4-il)-4-(2-fluorofenil)-5-metil-4H-[1,2,4]triazol o 3-(3´,5´-bis-trifluorometilbifenil-4-il)-5-metil-4-(3-trifluorometilbifenil)-4H-[1,2,4]triazol.
ARP040103392A 2003-09-22 2004-09-21 Derivados de triazol sustituidos como antagonistas de oxitocina AR045791A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
AR045791A1 true AR045791A1 (es) 2005-11-16

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103392A AR045791A1 (es) 2003-09-22 2004-09-21 Derivados de triazol sustituidos como antagonistas de oxitocina

Country Status (12)

Country Link
EP (1) EP1673355A1 (es)
JP (1) JP2007505888A (es)
AR (1) AR045791A1 (es)
BR (1) BRPI0414663A (es)
CA (1) CA2539297C (es)
MX (1) MXPA06003158A (es)
NL (1) NL1027084C2 (es)
PA (1) PA8613001A1 (es)
PE (1) PE20050950A1 (es)
TW (1) TW200526606A (es)
UY (1) UY28524A1 (es)
WO (1) WO2005028452A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
JP4954083B2 (ja) * 2004-11-18 2012-06-13 シンタ ファーマスーティカルズ コーポレイション Ｈｓｐ９０活性を調節するトリアゾール化合物
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
EP3501533A1 (en) 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
KR20190094187A (ko) 2016-12-21 2019-08-12 지앙수 헨그루이 메디슨 컴퍼니 리미티드 축합 고리기 아자시클로부틸 트리아졸 유도체, 이의 제조 방법 및 의약에서의 이의 용도
US20210040073A1 (en) 2016-12-28 2021-02-11 Jiangsu Hengrui Medicine Co., Ltd. Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine
TW202016091A (zh) * 2018-06-20 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｏｔｒ抑制劑的可藥用鹽、晶型及製備方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
WO2001058880A1 (fr) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
BR0110961A (pt) * 2000-05-19 2004-06-29 Merck Patent Gmbh Derivados de triazol
ES2240661T3 (es) * 2001-07-05 2005-10-16 Pfizer Products Inc. Sulfonil-heteroaril-triazoles como agentes antiinflamatorios y analgesicos.
CA2469042A1 (en) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists

Also Published As

Publication number Publication date
UY28524A1 (es) 2005-04-29
NL1027084A1 (nl) 2005-03-24
WO2005028452A1 (en) 2005-03-31
CA2539297A1 (en) 2005-03-31
TW200526606A (en) 2005-08-16
JP2007505888A (ja) 2007-03-15
PA8613001A1 (es) 2005-08-04
CA2539297C (en) 2010-07-20
NL1027084C2 (nl) 2006-01-24
EP1673355A1 (en) 2006-06-28
PE20050950A1 (es) 2005-11-11
BRPI0414663A (pt) 2006-11-21
MXPA06003158A (es) 2006-06-05
WO2005028452A9 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
NO20060219L (no) Forbindelser
EA200901659A1 (ru) Соединения пиперазина с гербицидным действием
RU2006120082A (ru) Производные пиридазин-3(2н)-она и их применение в качестве ингибиторов pde4
WO2005095409A3 (en) Tetrahydroquinoline derivatives and a process for preparing the same
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20040600A1 (es) Derivados de triazol como antagonistas del receptor de taquicinina
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
WO2005095395A3 (en) Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
WO2006055922A8 (en) Anthranilamide insecticides
MX9706382A (es) Derivados de benzoilo.
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
NO20061126L (no) Aminopyroner og deres anvendelse som ATM-inhibitorer
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.
TW200510377A (en) Novel compound having 4-pyridylalkylthio group as substituent
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
MY137761A (en) The use of n-arylhdrazine derivatives for combating non-crop pests
AR063790A1 (es) Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismos
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
AR039119A1 (es) Derivados de fenil amidas siliconadas utiles como microbiocidas
EP1908752A4 (en) NEW 2-CHINOLO DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure